Authors
Jesse C Nussbaum, Arthur Jackson, Dan Namarika, Jacob Phulusa, Jullita Kenala, Creto Kanyemba, Joseph N Jarvis, Shabbar Jaffar, Mina C Hosseinipour, Deborah Kamwendo, Charles M Van Der Horst, Thomas S Harrison
Publication date
2010/2/1
Journal
Clinical infectious diseases
Volume
50
Issue
3
Pages
338-344
Publisher
The University of Chicago Press
Description
Background . Cryptococcal meningitis is a major cause of human immunodeficiency virus (HIV)–associated morbidity and mortality in Africa. Improved oral treatment regimens are needed because amphotericin B is neither available nor feasible in many centers. Fluconazole at a dosage of 1200 mg per day is more fungicidal than at a dosage of 800 mg per day, but mortality rates remain unacceptably high. Therefore, we examined the effect of adding oral flucytosine to fluconazole.
Methods . From 13 February through 2 December 2008, HIV-seropositive, antiretroviral-naive patients experiencing their first episode of cryptococcal meningitis were randomized to receive (1) 14 days of fluconazole (1200 mg per day) alone or (2) in combination with flucytosine (100 mg/kg per day) followed by fluconazole (800 mg per day), with both groups undergoing 10 weeks of follow-up …
Total citations
20092010201120122013201420152016201720182019202020212022202320241161020221415129161118128156